



Amyloidosis is a rare disorder caused by extracellular deposition of 
insoluble amyloid fibrils that disrupt the architecture of the affected 
tissues and cause organ dysfunction. The clinical phenotype depends 
on the involvement of particular organs and the type of deposition. 
The frequency of cardiac involvement varies among the various types 
of amyloidoses. Classification of amyloidoses is based on the type 
of amyloid protein and its identity. More than 30 types of proteins 
are known to cause amyloid deposition. The three most common 
forms of amyloidosis are light-chain amyloidosis (AL), secondary 
amyloidosis (AA), and transthyretin-related amyloidosis (ATTR). In AL 
amyloidosis, deposits are composed of monoclonal immunoglobulin 
(Ig) kappa or lambda light chains. The estimated prevalence in the 
UK is 3-5/year per 1,000,000 inhabitants [1]. Approximately 250 new 
patients with AL amyloidosis are detected per year in Poland [2]. 
Involvement of the heart in AL amyloidosis occurs in 50% of cases, 
whereas isolated cardiac AL amyloidosis concerns < 5% of patients 
[3]. Cardiac amyloidosis has the worst prognosis on any involved 
organ, and AL amyloidosis is the most serious form of the disease 
[4]. Intrinsic properties of the amyloid deposition, host immune 
response, and the amyloid nanoenvironment play key roles in the 
cardiotoxicity [5]. Advanced cardiac involvement is the strongest 
predictor of poor patient outcome, and median survival for untreated 
patients with congestive heart failure in course of AL is < 6 months 
[6]. Therefore, early recognition of cardiac AL amyloidosis with 
implementation of novel therapeutic strategies is crucial to help with 
better clinical outcomes of patients [7]. Recently published data show 
that administration of modern therapies leads to prolonged remission 
and extended life expectancy.
Clinical features
Establishing a diagnosis of systemic amyloidosis is complicated 
because of the variety of nonspecific clinical features of the 
disease depending on the type and number of organs affected 
[2]. The most common clinical signs of AL amyloidosis include 
nephrotic syndrome (70%), restrictive cardiomyopathy (60%), 
peripheral neuropathy (20%), hepatomegaly with elevated levels of 
liver enzymes (70%), hypotension (30%), macroglossia, muscle 
involvement, skin manifestations, and bleeding diathesis [8]. Patients 
complain of fatigue, loss of body weight, and carpal tunnel syndrome. 
Macroglossia, dysphagia, speech impairment, nail dystrophy, easy 
bruising, and peripheral purpura (called raccoon or panda eyes) are 
pathognomonic stigmata of disease.
Cardiac involvement manifestation
Cardiac manifestation occurs in one-third to one-half of patients 
suffering from AL amyloidosis [9]. Patients with initially nonspecific 
cardiac symptoms are undiagnosed until development of severe 
heart failure [10]. Isolated primary cardiac amyloidosis is a 
very rare manifestation of AL amyloidosis (< 5% of patients) and is 
associated with a poor prognosis [3]. The classical presentation of AL 
cardiomyopathy is a rapid progression of symptoms of diastolic heart 
failure, which may result in many serious heart consequences such 
as arrhythmias, syncope, ischemic heart disease, and intracardiac 
thrombus formation. Atrial fibrillation is seen in 9% of patients [11]. 
Hypotension is common in AL cardiac amyloidosis [12]. Progressive 
heart failure and electromechanical dissociation are the most common 
causes of death in patients with cardiac amyloidosis [13].
Diagnostic approach to light-chain 
cardiac amyloidosis and its differential 
diagnosis
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Clinical signs and results of noninvasive diagnostic investigation 
facilitate establishment of a diagnosis of amyloidosis; they, however, 
do not differentiate the subtypes of the disease. Undoubtedly, 
identification of the amyloid source is crucial for the implementation 
of an appropriate therapy and to avoid severe therapeutic errors. 
According to updated noninvasive consensus diagnostic criteria 
for AL amyloidosis, cardiac involvement is defined as mean left 
ventricular (LV) wall thickness on echocardiography > 12 mm 
with no other causes found and the N-terminal fragment of pro-brain 
natriuretic peptide (NT-proBNP) level > 39 pmol/l in the absence of 
renal failure or atrial fibrillation [14]. The diagnosis of suspected AL 
cardiac amyloidosis requires cooperation between hematologists and 
cardiologists (Fig. 1) [15].
Histological findings
Routine histopathologic diagnosis of amyloidosis requires identification 
of the amyloid, based on tissue biopsy. The amyloid protein binds 
Congo red dye or thioflavin T, producing apple green birefringence 
under polarized light [16]. Biopsy of easily accessible sites, such as 
abdominal fat, minor salivary glands, the rectum, or gingiva can spare 
patients endomyocardial biopsy (EMB). Fine-needle aspiration of 
abdominal fat is positive in 70% of patients with AL amyloidosis [17]. 
Histopathological examination is indispensable; however, it is unable 
to differentiate between amyloid subtypes [18]. Confirmation of AL 
amyloidosis requires the identification of kappa or lambda chains in 
amyloid deposits. Determination of the amyloid subtype is performed 
using the following methods: immunohistochemical staining, 
immunoelectron microscopy (IEM), and laser microdissection 
with mass spectrometry. Although not widely available, proteomic 
evaluation of amyloid deposits by mass spectrometry allows for highly 
sensitive and specific results to determine the precise component of 
the amyloid deposits [4].
EMB may allow diagnosis of AL cardiac amyloidosis in cases where 
other tissue biopsies are not available. This is a gold standard 
diagnostic tool directly proving the presence of amyloid infiltration; 
however, it should be performed only in specialized centers by 
experienced operators [19]. EMB is an invasive procedure, 
with the risk of serious complications. During the procedure, heart 
catheterization is performed, enriching the operator information from 
Fig. 1. Diagnostic algorithm for cardiac AL amyloidosis
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hemodynamic measurements [4]. Right ventricular EMB is routinely 
performed; however, recently, LV EMB appears diagnostically more 
contributive [20, 21]. The sensitivity of cardiac biopsy varies 
depending on the phase of amyloid infiltration. In a group of patients 
with unexplained cardiomyopathy, EMB turned out to be more 
sensitive than initial clinical diagnosis (100% vs. 81%) in a subgroup 
of AL amyloidosis patients [22].
Hematological assessment
All patients with suspected AL amyloidosis should undergo 
hematological evaluation to determine the percentage of bone marrow 
plasma cells present and the presence of monoclonal protein to rule 
out concomitant multiple myeloma and other hematological disorders. 
Electrophoresis and immunofixation of serum and urine should be 
performed to display the presence of monoclonal (M) protein and 
abnormal serum free light chain (FLC) ratio in AL amyloidosis. 
Monoclonal IgG protein (35%), IgA protein (10%), IgM protein (5%), 
and IgD protein (1%), as well as free light chains (49%), can be found 
in AL amyloidosis patients [23]. Lambda light chains are present in 
70%, kappa type in 25%, and the biclonal type in 5% of patients [24]. 
Typically, lambda chains prevail over kappa in the ratio of 3:1, which 
differs from multiple myeloma, in which this ratio is 2:3. Bone marrow 
biopsy in AL amyloidosis may reveal an increased percentage 
of plasma cells that may appear morphologically normal, with a 
median percentage of < 10% [25]. Immunoperoxidase staining or 
flow cytometric analysis of specimens of the involved bone marrow 
can demonstrate clonal excess of plasma clone cells. Bone marrow 
biopsy is 50% sensitive for detecting deposits of amyloid, but, 
performed with fat pad aspirate, can be up to 85% sensitive [26].
Cardiac biomarkers
Biomarker-based staging systems are crucial for patient stratification 
in clinical trials and to implement proper therapy regarding patients’ 
suitability for high-dose chemotherapy and autologous stem cell 
transplantation. The expert community has stated that NT-proBNP 
is an analytically validated biomarker for use as a surrogate and end 
point for survival in cardiac AL amyloidosis patients. NT-proBNP is an 
indicator of cardiac response [27]. Long-term outcomes of patients 
with AL cardiac amyloidosis are more likely related to underlying clonal 
disorders; thus, the revised Mayo staging system for AL amyloidosis 
includes serum differences between involved and uninvolved light 
chains (FLC-diff) in the risk stratification of patients [28].
Noninvasive heart-imaging methods
Noninvasive heart-imaging methods play a key role in the diagnostic 
approach to cardiac  AL amyloidosis; however, they cannot distinguish 
the subtype of amyloid infiltration.
Echocardiography
Echocardiography remains an essential diagnostic method providing 
assessment of the function and morphology of the heart. Standard 
echocardiography with tissue Doppler may reveal certain or all 
characteristics, but all are nonspecific features of cardiac amyloidosis. 
Classic abnormalities include concentric LV wall thickening, moderate- 
to-severe diastolic dysfunction, restrictive filling pattern, biatrial 
dilatation, pericardial and pleural effusions, as well as diffuse valvular 
and interatrial septal thickening [29]. Echocardiography reveals the 
“granular”, “sparkling” appearance of ventricular thickened myocardium 
[30]. In amyloid cardiomyopathy, a restrictive pattern of LV filling with high 
filling pressures is considered pathognomonic and indicates increased 
ventricular stiffness occurring in the late stages of cardiac amyloidosis 
[31]. Left atrial dysfunction in the presence of the sinus rhythm is 
associated with an increased risk of thrombus formation [32] and a 
worse outcome. Myocardial strain imaging is a useful echocardiographic 
technique detecting systolic impairment with strain and strain rate and is 
more sensitive than the standard tissue Doppler [33]. Two-dimensional 
feature-tracking imaging (FTI) and speckle-tracking imaging are 
methods allowing myocardial motion analysis frame by frame throughout 
the cardiac cycle. The FTI technique helps to distinguish between LV 
thickening in cardiac amyloidosis and hypertrophic cardiomyopathy.
Cardiovascular magnetic resonance
Cardiovascular magnetic resonance (CMR) is sensitive in detecting 
amyloid cardiomyopathy and has excellent spatial resolution for tissue 
characterization. It provides imaging of the atrial structure, heart 
systolic function, and morphology of restrictive cardiomyopathy [34]. 
Late gadolinium enhancement (LGE), expansion of the extracellular 
volume (ECV), and abnormally prolonged T1 times (before or after 
contrast) are characteristic features visible on CMR in patients with 
amyloid cardiomyopathy. LGE reveals pathognomonic endocardial and 
myocardial wall enhancement, which is highly sensitive and specific 
for cardiac amyloidosis [35]. The prevalence of myocardial LGE can 
increase up to 97% and different LGE patterns can be observed, e.g., 
”patchy” [36]. Gadolinium uptake in cardiac amyloidosis is observed in 
the atria, which is rare in other cardiomyopathies [37]. Measurement 
of ECV indicates myocardial extracellular matrix expansion even in 
segments in which LGE cannot be seen [38]. CMR T1 mapping reveals 
a myocyte response to amyloid infiltration through measurement of the 
native (noncontrast) myocardial longitudinal relaxation time of tissue.
Electrocardiography
Abnormalities are found in 90% of patients with AL cardiac 
involvement on electrocardiography (ECG) [39]; however, this 
method is not sufficient to establish a diagnosis. Low voltage on ECG 
is a characteristic feature, present in 56% of patients [40]. Other 
classic findings include atrial fibrillation/flutter (20%), first-degree 
atrioventricular block (21%), nonspecific intraventricular conduction 
delays (16%), and second- or third-degree atrioventricular block (3%) 
[39]. Ventricular tachycardia (5%), left and right bundle branch block, 
and pseudoinfarct patterns (60%) can be also be observed [41].
Nuclear imaging
Several nuclear medicine imaging techniques have become available 
for the diagnosis and prognostic stratification of cardiac amyloidosis 
[42]. Bone scintigraphy using radiolabeled 99mTc-3,3-diphosphono-
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1,2-propanodicarboxylic acid tracer is useful in differentiating between 
ATTR and AL cardiac amyloidoses, revealing a positive uptake in 
ATTR cardiac amyloidosis [43] and false-positive results in AL cardiac 
amyloidosis [44].
Differential diagnosis of cardiac AL 
amyloidosis
It is important to distinguish the subtypes of amyloidosis, monoclonal 
Ig deposition diseases (MIDDs), and various cardiologic causes of 
LV hypertrophy.
Based on the nature of the amyloid precursor protein, several forms 
of amyloidosis with distinct clinical features are recognized. The most 
common types of cardiac amyloidosis are presented in table I.
All amyloid deposits misfold to beta-pleated fibrillar configuration 
and demonstrate staining with Congo red and bind with thioflavin T; 
however, only direct examination of the amyloid deposits enables 
determination of the subtype of the disease. The echocardiographic 
appearance is almost indistinguishable between the subtypes of 
cardiac amyloidosis.
The MIDDs
The MIDDs are clonal plasma cell proliferative disorders, in which 
Ig light or heavy chain fragments form tissue deposits, which lead to 
organ dysfunction. In contrast to amyloid deposits, the MIDD tissue 
deposits are granular and do not stain positive with Congo red and 
thioflavin T. Table II shows the characteristic features of MIDD in 
comparison with amyloidosis.
Involvement of the heart in MIDD may mimic AL amyloidosis. 
The echocardiographic appearance is similar to that in cardiac 
amyloidosis. Heart failure and arrhythmias may occur.
Non-Q-wave heart infarction
Non-Q-wave heart infarction can be misdiagnosed in the presence of 
AL cardiac amyloidosis infiltrating small vessels in the myocardium 
[49]. Clinically, patients present angina-like chest pain. Troponin level 
elevation may represent ongoing myocyte necrosis and has been 
shown to be a negative prognostic factor [50].
LV hypertrophy
Various causes of LV hypertrophy, including hypertensive heart 
disease, hypertrophic cardiomyopathy, Fabry disease, mitochondrial 
cardiomyopathy, and other causes of restrictive cardiomyopathy such 
as infiltration with metastatic cancer [10], should also be taken into 
account. Hypertensive heart disease, hypertrophic cardiomyopathy, 
or Fabry disease with LV hypertrophy is associated with an increased 
or normal electrocardiogram voltage, unlike the low-voltage 
electrocardiogram observed in amyloid infiltration. Echocardiographic 
features such as valve thickening, thickened interatrial septum, and 
diffuse increase in echogenicity help to distinguish cardiac amyloidosis 
from other causes of restrictive cardiomyopathy and LV hypertrophy. 
Specific amyloidosis CMR findings, such as LGE, are not expected in 
other causes of LV hypertrophy and restrictive cardiomyopathy.
Table I. Most common subtypes of amyloidosis [4, 26, 45-47]
Cardiac amyloidosis Pathophysiology Average age at presentation
Frequency of cardiac 
involvement Comments
AL Immunoglobulin light chain > 50 years 50% –
Light chain amyloidosis Underlying plasma cell dyscrasia
ATTR Mutant transthyretin > 40 years 90% Certain mutations can cause 
progressive cardiomyopathy, leading 
to heart failure [45]
Hereditary amyloidosis Genetic mutations cause misfolding of hepatic-
derived transthyretin into amyloid material
SCA Wild-type transthyretin > 65 years Almost 100% Occurs most often in men [4]; 
manifests as congestive heart failure: 
in 91% involves atria [46]
Senile cardiac amyloidosis Age-related protein deposition
AA Serum amyloid A 60-70 years Rare May occur in 20s-30s with severe 
inflammatory disease [4]; does not 
affect heart in clinically significant 
manner [47]
Secondary amyloidosis Chronic inflammatory conditions, malignancy 
leading to increased hepatic production of the 
acute phase reactant serum amyloid A
Table II. Characteristic features of plasma cell proliferative disorders forming tissue deposits [3, 48]
Feature Monoclonal immunoglobulin deposition diseases (MIDDs) Amyloidosis
Subtypes 90% Light chain deposition disease (LCDD) AL amyloidosis
10% Light and heavy chain deposition disease (LHCDD) AH amyloidosis (heavy-chain amyloidosis)
Heavy chain deposition disease (HCDD)
Structure of deposits LCDD: fragments of light chains; k chains (68%), l chains (32%); normal sized or 
short
AL amyloidosis: normal-sized or enlarged light 
chains (l type – 75%, k type – 25%)
LHCDD: associated heavy chains
AH amyloidosis: short heavy chains
HCDD: short (truncated) heavy chains




Diagnosis of cardiac AL amyloidosis should be considered in adult 
patients with unexplained heart failure and an echocardiogram 
showing increasing wall thickness with a nondilated LV cavity, 
especially in the absence of a history of hypertension.
Modern diagnostic techniques, particularly advanced 
echocardiography and cardiovascular magnetic resonance findings, 
are helpful in supporting the diagnosis of AL amyloidosis. Early 
identification and diagnosis of AL amyloidosis is important to provide 
timely medical therapy. Administration of modern therapies has 
not only halted the progression of the disease but has also led to 
prolonged remission and improvement of the outcomes.
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